Health Care

UnitedHealth Group faces regulatory scrutiny over Medicare reimbursement tactics, amid investor doubts and a looming earnings release that could shape its future.

Amgen’s $1.4 billion oncology acquisition spree signals a bold push toward cancer therapies, promising pipeline growth amid a biotech boom and investor optimism.

Siemens Healthineers’ FDA approval of a helium‑free MRI system boosts cost‑efficiency, expands market reach, and signals sustainable growth in medical imaging.

Advicenne S.A.: Paris‑based pharma innovating rare renal disease treatments—Sibnayal, Levidcen, and more—boosting patient care and market growth.

Idorsia’s Phase‑III lucerastat data show kidney‑protective effects in Fabry disease, while CEO Dr. Srishti Gupta’s JP Morgan presentation highlights a pipeline of first‑in‑class medicines poised to drive future growth and investor interest.

Explore how Cronos Group’s 2027 export launch and potential European gas deal could reshape its cannabis business and diversify revenue.

Guardant Health insider sale sparks volatility concerns: negative P/E, shaky growth, and strategic recalibration needed for investors to assess sustainability.

Explore EBR Systems Inc., a Sunnyvale‑based medical device leader pioneering wireless cardiac pacing, its recent stock swings, financial challenges, and future prospects.

MBX Biosciences, a $1.38 billion biotech poised for a hypoparathyroidism breakthrough, will reveal Phase 2 canvuparatide data in Q2 2026, sparking a potential Phase 3 launch and investor momentum.

Ideaya Biosciences